latest update:
[TrialBase DB]

trial summary · NCT07629583

To Evaluate the Effects of Cevostamab in Participants With Systemic Lupus Erythematosus With or Without Active Lupus Nephritis

An Open-Label, Multicenter, Phase Ib Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Cevostamab in Patients With Systemic Lupus Erythematosus With or Without Active Lupus Nephritis

Trial record from the TrialBase DB dataset, status RECRUITING, condition Lupus Erythematosus, Systemic, sponsored by Genentech, Inc.. Facts below are exported values from the current release, not inferred or edited prose.

registry NCT07629583phase PHASE1enrollment 46start 2026-10-31

Summary

The brief summary is the registry's published description, capped for length. Field definitions, types, and provenance rules are in the data dictionary.

The study will evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of cevostamab in participants with systemic lupus erythematosus (SLE) with or without active lupus nephritis (LN).

Source record: https://clinicaltrials.gov/study/NCT07629583

Facts

registry idNCT07629583
primary registryclinicaltrials-gov
recruitment statusRECRUITING
phasePHASE1
study typeINTERVENTIONAL
lead conditionLupus Erythematosus, Systemic
sponsorGenentech, Inc.
sponsor classINDUSTRY
enrollment46
start date2026-10-31
primary completion2030-03-29
completion2030-03-29
results postednot reported

Conditions

  • Lupus Erythematosus, Systemic

Interventions

  • Cevostamab
  • Tocilizumab

Countries

  • France
  • Spain

Intervention types: DRUG

Work with this record